Trials / Active Not Recruiting
Active Not RecruitingNCT03531255
Pegcetacoplan Long Term Safety and Efficacy Extension Study
An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | Complement (C3) Inhibitor |
Timeline
- Start date
- 2018-08-27
- Primary completion
- 2025-11-29
- Completion
- 2026-07-01
- First posted
- 2018-05-21
- Last updated
- 2026-04-06
Locations
62 sites across 21 countries: United States, Australia, Belgium, Bulgaria, Canada, Colombia, France, Germany, Hong Kong, Japan, Malaysia, Mexico, Peru, Philippines, Russia, Serbia, Singapore, South Korea, Spain, Thailand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03531255. Inclusion in this directory is not an endorsement.